Abstracts tagged "etanercept"

Abstract Number: 2549 • 2012 ACR/ARHP Annual Meeting
Induction of Remission in Patients with up to 12 Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 52 Weeks
Paul Emery¹, Mohammed Hamoudeh², Oliver FitzGerald³, Bernard Combe⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Jack Bukowski⁶, Ronald Pedersen⁵, Andrew S. Koenig⁷ and Bonnie Vlahos⁵, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Medicine - Rheumatology, Hamad Medical Corporation, Doha, Qatar, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Pfizer, Inc., Collegeville, PA
Background/Purpose: In the COMET study, etanercept (ETN) plus methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA) yielded high clinical remission rates,1 but whether…
Abstract Number: 1147 • 2012 ACR/ARHP Annual Meeting
Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS
Gerd Horneff¹ and Ingrid Kaul², ¹Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ²Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany
Definition of improvement thresholds in juvenile idiopathic arthritis (JIA) using the JADAS Background/Purpose: Evaluation of disease activity in JIA is fundamental in clinical assessment. The…
Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Masatoshi Hayashi¹, Toshihisa Kojima², Naoki Ishiguro³, Tomonori Kobayakawa⁴ and Toshihisa Kanamono¹, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁴Orthopedic Surgery, Nagoya university, Nagoya, Japan
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…
Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Susanne Drynda¹, David Leesch², Marietta Gloetzner² and Joern Kekow², ¹Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Ankur A. Kamdar¹, Patricia C. Giclas² and Barry L. Myones³, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Pediatric Allergy and Immunology, National Jewish Health, Denver, CO, ³Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Heather Jones¹, Annette Szumski² and Andrew S. Koenig³, ¹Pfizer Inc., Collegeville, PA, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…
Abstract Number: 2002 • 2012 ACR/ARHP Annual Meeting
Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise?
Petra C.E. Hissink Muller¹, Bahar Yildiz¹, Cornelia F. Allaart², Danielle M.C. Brinkman³, Marion A. J. Van Rossum⁴, J. Merlijn Van den Berg⁵, Lisette W.A. Van Suijlekom-Smit⁶, Rebecca Ten Cate¹ and Martine C. de Vries⁷, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ⁵Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, ⁶Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁷Medical Ethics and Health Law, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: It is an ethical requirement for setting up a randomized controlled trial (RCT) that the physician-investigator must have genuine uncertainty about the therapeutic options.…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Machaon Bonafede¹, Crystal Watson², George Joseph², Nicole Princic¹ and David J. Harrison², ¹Thomson Reuters Healthcare, Cambridge, MA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Paul Emery¹, Piotr Wiland², Wolfgang Spieler³, Jean Dudler⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁵, Andrew S. Koenig⁵, Bonnie Vlahos⁵ and Sameer Kotak⁶, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Maria Victoria Hernández¹, Miguel A. Descalzo², Juan D. Cañete¹, Raimon Sanmarti³ and BIOBADASER Study Group⁴, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Research Unit. Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting
Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results
Anjali Patwardhan¹, Kelly A. Rouster-Stevens², Harry L. Gewanter³, Grant D. Syverson⁴, Renee F. Modica⁵, Kara M. Schmidt⁶ and Charles H. Spencer⁷, ¹Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ²Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, ³Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, ⁴Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, ⁵Pediatric Rheumatology, University of Florida, Gainesville, FL, ⁶Pediatric Rheumatology, Univ of Louisville, Louisville, KY, ⁷Rheumatology, Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders. Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Michele Hooper¹, Deborah Wenkert², Bojena Bitman³, Virgil C. Dias⁴, Yessinia Bartley⁵, Julie Wang⁶ and Julia R. Gage⁷, ¹Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ²Inflammation TA, Amgen Inc., Thousand Oaks, CA, ³Amgen, Inc., San Francisco, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Assent Consulting, Solana Beach, CA, ⁶Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, ⁷Gage Medical Writing, LLC, Oak Park, CA
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].